Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial. [electronic resource]
Producer: 20120201Description: 346-53 p. digitalISSN:- 1651-2065
- Aged
- Antineoplastic Agents, Hormonal -- administration & dosage
- Cardiovascular Diseases -- complications
- Combined Modality Therapy
- Estradiol -- administration & dosage
- Estrogens -- administration & dosage
- Flutamide -- administration & dosage
- Humans
- Infusions, Parenteral
- Male
- Neoplasm Metastasis
- Orchiectomy
- Prognosis
- Prostatic Neoplasms -- pathology
- Risk Factors
- Triptorelin Pamoate -- administration & dosage
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.